The estimated Net Worth of Patrick O'brien is at least 20.1 百万$ dollars as of 3 January 2024. Mr. brien owns over 33,190 units of Arrowhead Pharmaceuticals stock worth over 9,724,222$ and over the last 10 years he sold ARWR stock worth over 8,852,798$. In addition, he makes 1,552,940$ as General Counsel at Arrowhead Pharmaceuticals.
Patrick has made over 11 trades of the Arrowhead Pharmaceuticals stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 33,190 units of ARWR stock worth 1,140,408$ on 3 January 2024.
The largest trade he's ever made was exercising 90,000 units of Arrowhead Pharmaceuticals stock on 8 February 2021 worth over 469,800$. On average, Patrick trades about 20,517 units every 95 days since 2014. As of 3 January 2024 he still owns at least 464,385 units of Arrowhead Pharmaceuticals stock.
You can see the complete history of Mr. brien stock trades at the bottom of the page.
Patrick C. O'Brien J.D. serves as General Counsel of the Company. Mr. O’Brien has practiced in the healthcare legal field for over 25 years. Before joining the Company, from 2012 to 2014, Mr. O’Brien was with Shire, as global pharmaceutical company, where he was Group Vice President, Law. Immediately prior to working with Shire he was a partner with the international law firm of Holland & Knight LLP in its Washington, DC office. In 2010, Mr. O’Brien co-founded the law firm O’Brien Gould PLLC which joined Holland & Knight in 2011. From 2009 to 2010, Mr. O’Brien was a partner in Burke O’Neil LLC. From 2001 to 2009 Mr. O’Brien served in several legal roles with Johnson & Johnson, including serving as Vice President of Law for J&J’s Centocor Ortho-Biotech unit. Mr. O’Brien previously served as Regulatory Counsel with the United States Food & Drug Administration. Mr. O’Brien was awarded a BS in Pharmacy and a PharmD from the University of Arizona before completing a residency in Clinical Pharmacy with the University of Illinois at Chicago Hospital. He was also awarded his JD from the University of Arizona.
As the General Counsel of Arrowhead Pharmaceuticals, the total compensation of Patrick Brien at Arrowhead Pharmaceuticals is 1,552,940$. There are 3 executives at Arrowhead Pharmaceuticals getting paid more, with Christopher Anzalone having the highest compensation of 2,216,260$.
Patrick Brien is 56, he's been the General Counsel of Arrowhead Pharmaceuticals since 2015. There are 7 older and 9 younger executives at Arrowhead Pharmaceuticals. The oldest executive at Arrowhead Pharmaceuticals Inc. is Dr. Mark Seefeld, 67, who is the Head of Toxicology & VP.
Patrick's mailing address filed with the SEC is 177 E. COLORADO BLVD, SUITE 700, PASADENA, CA, 91105.
Over the last 21 years, insiders at Arrowhead Pharmaceuticals have traded over 129,489,075$ worth of Arrowhead Pharmaceuticals stock and bought 176,205 units worth 991,784$ . The most active insiders traders include David M Knott、Christopher Richard Anzalone、Kenneth Allen Myszkowski. On average, Arrowhead Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of 868,068$. The most recent stock trade was executed by Tracie Oliver on 2 July 2024, trading 9,394 units of ARWR stock currently worth 237,480$.
arrowhead pharmaceuticals is a clinical stage, nasdaq listed (ticker arwr) company developing medicines that treat intractable diseases by silencing the genes that cause them. using a broad portfolio of rna chemistries and efficient modes of delivery, our therapies trigger the rna interference mechanism to induce rapid, deep and durable knockdown of target genes. rna interference, or rnai, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. our rnai-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. our targeted rnai molecule (trimtm) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. the trim platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing
Arrowhead Pharmaceuticals executives and other stock owners filed with the SEC include: